Citius Oncology’s wholesaler shipments rise sharply while institutional orders grow modestly
Citius Oncology ($CTOR) reported preliminary sales of 792 Lymphir units to US wholesalers for its fiscal fourth quarter of 2026, up 120% from 360 in the preceding quarter. Separately, prescribing centers ordered 950 vials from wholesalers, compared with 926 previously. Fifty-four institutions have now ordered the cutaneous T-cell lymphoma treatment, up from the 44 reported in the company’s last update. The figures indicate expanding distribution, but wholesaler purchases and institutional orders
0